Autres langues eFFECTOR Therapeutics, Inc.

Actions

EFTR

US28202V2079

Recherche biotechnologique et médicale

Temps Différé OTC Markets 20:27:09 21/08/2026			Varia. 5j.	Varia. 1 janv.
0,000300 ^USD	-62,50 %		+50,00 %	+50,00 %

10/09/24	Tyra Biosciences nomme Doug Warner directeur médical	MT
24/06/24	Mise à jour sectorielle : Les actions du secteur de la santé augmentent en fin d'après-midi	MT

Autres langues

10/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer
13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index
02/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K
24/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading
24/06/24	Top Midday Decliners
24/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
09/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
04/04/24	Health Care Down on Retreat From Risk -- Health Care Roundup
04/04/24	Top Midday Decliners
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
04/04/24	EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
26/03/24	Top Premarket Decliners
26/03/24	EFFECTOR Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
25/03/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
05/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
25/01/24	EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules